Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Aniline Compounds / pharmacology Animals Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal, Humanized Antineoplastic Agents / pharmacology Apoptosis / drug effects Breast Neoplasms / drug therapy Bridged Bicyclo Compounds, Heterocyclic / pharmacology CD8-Positive T-Lymphocytes Cell Line, Tumor / drug effects Cell Survival / drug effects Clustered Regularly Interspaced Short Palindromic Repeats Drug Combinations Female Genes, myc / drug effects HEK293 Cells Heterografts Humans Immunotherapy Metformin / pharmacology Mice Mice, Transgenic Proto-Oncogene Proteins c-bcl-2 Sulfonamides / pharmacology bcl-X Protein

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 02 2019
Historique:
received: 07 04 2018
accepted: 17 01 2019
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 12 4 2019
Statut: epublish

Résumé

Elevated MYC expression sensitizes tumor cells to apoptosis but the therapeutic potential of this mechanism remains unclear. We find, in a model of MYC-driven breast cancer, that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-X

Identifiants

DOI: 10.1038/s41467-019-08541-2 PMID: 30728358 PMC: PMC6365524
pubmed: 30728358
doi: 10.1038/s41467-019-08541-2
pii: 10.1038/s41467-019-08541-2
pmc: PMC6365524
doi:

Substances chimiques

Aniline Compounds 0
Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents 0
BCL2 protein, human 0
Bcl2l1 protein, mouse 0
Bridged Bicyclo Compounds, Heterocyclic 0
Drug Combinations 0
Proto-Oncogene Proteins c-bcl-2 0
Sulfonamides 0
bcl-X Protein 0
atezolizumab 52CMI0WC3Y
Metformin 9100L32L2N
venetoclax N54AIC43PW
navitoclax XKJ5VVK2WD

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

620

Commentaires et corrections

Type : ErratumIn

Références

PLoS One. 2012;7(3):e33411
pubmed: 22448244
Cancer Cell. 2015 Jul 13;28(1):129-40
pubmed: 26175417
J Clin Invest. 2012 Jun;122(6):2018-31
pubmed: 22622039
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Breast Cancer Res. 2013;15(5):317
pubmed: 24172207
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cell. 2016 Jun 16;165(7):1560
pubmed: 27315468
J Immunol. 2011 Mar 1;186(5):2772-9
pubmed: 21263073
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
EMBO J. 1998 Jan 15;17(2):384-95
pubmed: 9430630
Cell Mol Life Sci. 2012 Mar;69(6):931-4
pubmed: 22033838
Clin Cancer Res. 2014 May 15;20(10):2508-15
pubmed: 24682417
Nat Med. 2016 Apr;22(4):427-32
pubmed: 26950360
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Cell. 2007 Jun 29;129(7):1337-49
pubmed: 17604722
Clin Cancer Res. 2012 Aug 15;18(16):4385-96
pubmed: 22745104
Nat Rev Cancer. 2002 Oct;2(10):764-76
pubmed: 12360279
Cell Death Differ. 2014 Feb;21(2):196-205
pubmed: 24162660
EMBO J. 2007 Feb 21;26(4):1055-67
pubmed: 17268552
ESMO Open. 2018 Oct 20;3(6):e000453
pubmed: 30425847
Diabetes Care. 2012 Apr;35(4):731-7
pubmed: 22442396
J Clin Invest. 2013 Jul;123(7):2756-63
pubmed: 23863633
Nature. 2015 Jan 29;517(7536):583-8
pubmed: 25494202
Oncogene. 2016 Apr 7;35(14):1832-46
pubmed: 26165838
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):E388-97
pubmed: 22308451
Nature. 2004 Nov 18;432(7015):307-15
pubmed: 15549092
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cell Metab. 2016 Apr 12;23(4):569-70
pubmed: 27076070
Cancer Res. 1999 Jun 15;59(12):2759-65
pubmed: 10383126
Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1839-48
pubmed: 23589839
Cell Death Differ. 2011 Sep;18(9):1414-24
pubmed: 21415859
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Cancer Cell. 2007 Jul;12(1):66-80
pubmed: 17613437
Nature. 2017 Jun 7;546(7657):234-242
pubmed: 28593971
Small GTPases. 2018 May 4;9(3):274-282
pubmed: 27532209
F1000Res. 2016 Mar 29;5:
pubmed: 27081479
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6
pubmed: 19004807
Br J Cancer. 2000 Dec;83(12):1688-95
pubmed: 11104567
Clin Cancer Res. 2016 May 15;22(10):2329-34
pubmed: 27016309
EMBO J. 2015 Jun 3;34(11):1554-71
pubmed: 25896507
Nature. 2015 Sep 17;525(7569):384-8
pubmed: 26331541
J Exp Med. 2012 Apr 9;209(4):679-96
pubmed: 22430491
Nature. 2014 Jul 24;511(7510):483-7
pubmed: 25043018
Cell Rep. 2014 Sep 11;8(5):1347-53
pubmed: 25176652
Blood. 2013 Mar 21;121(12):2285-8
pubmed: 23341542
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Blood. 2009 Feb 26;113(9):1982-91
pubmed: 19060243
Int J Mol Med. 2002 Feb;9(2):189-96
pubmed: 11786932
J Pathol. 2003 Sep;201(1):75-82
pubmed: 12950019
Cancer Cell. 2006 Nov;10(5):375-88
pubmed: 17097560
Nat Rev Cancer. 2016 Nov;16(11):749
pubmed: 28704361
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616
Stem Cell Reports. 2015 Sep 8;5(3):448-59
pubmed: 26352799
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancer Res. 1995 Sep 1;55(17):3915-27
pubmed: 7641211
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Mol Cell. 2005 Feb 18;17(4):525-35
pubmed: 15721256
Cell Metab. 2014 Dec 2;20(6):953-66
pubmed: 25456737

Auteurs

Heidi M Haikala (HM)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 360 Longwood Ave, 02215, Boston, MA, USA.
ORCID: 0000-0002-8465-8568

Johanna M Anttila (JM)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Elsa Marques (E)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Tiina Raatikainen (T)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Mette Ilander (M)

Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.

Henna Hakanen (H)

Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.

Hanna Ala-Hongisto (H)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Mariel Savelius (M)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Diego Balboa (D)

Research Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.
ORCID: 0000-0002-4784-5452

Bjoern Von Eyss (B)

Leibniz Institute of Age Research, Fritz Lipmann Institute e.V, Beutenbergstraße 11, 07745, Jena, Germany.
ORCID: 0000-0002-4731-6841

Vilja Eskelinen (V)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Pauliina Munne (P)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland.

Anni I Nieminen (AI)

Department of Biosciences and Institute of Biotechnology, University of Helsinki, Viikinkaari 5, 00790, Helsinki, Finland.

Timo Otonkoski (T)

Research Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.
ORCID: 0000-0001-9190-2496

Julia Schüler (J)

Oncotest GmbH, (Now part of Charles River Laboratories Inc, 251 Ballardvale St, Wilmington, MA 01887, USA), Freiburg, Germany.

Teemu D Laajala (TD)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 3, 00290, Helsinki, Finland.
Department of Mathematics and Statistics, University of Turku, Vesilinnantie 5, 20500, Turku, Finland.

Tero Aittokallio (T)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 3, 00290, Helsinki, Finland.
Department of Mathematics and Statistics, University of Turku, Vesilinnantie 5, 20500, Turku, Finland.
ORCID: 0000-0002-0886-9769

Harri Sihto (H)

Research Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki, P.O. Box 63 (Street address: Haartmaninkatu 8), 00290, Helsinki, Finland.
Department of Oncology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland.
ORCID: 0000-0001-5265-5509

Johanna Mattson (J)

Department of Oncology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland.

Päivi Heikkilä (P)

Department of Pathology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 3, 00290, Helsinki, Finland.

Marjut Leidenius (M)

Breast Surgery Unit, Helsinki University Hospital, Kasarmikatu 11-13, 00290, Helsinki, Finland.

Heikki Joensuu (H)

Research Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki, P.O. Box 63 (Street address: Haartmaninkatu 8), 00290, Helsinki, Finland.
Department of Oncology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland.

Satu Mustjoki (S)

Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Haartmaninkatu 8, 00290, Helsinki, Finland.
ORCID: 0000-0002-0816-8241

Panu Kovanen (P)

Department of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 3, 00290, Helsinki, Finland.

Martin Eilers (M)

Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Würzburg, Am Hubland, D-970074, Germany.
ORCID: 0000-0002-0376-6533

Joel D Leverson (JD)

Oncology Development, AbbVie, Inc., 1 N Waukegan Road, North Chicago, IL, 60064, USA.

Juha Klefström (J)

Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki, P.O. Box 63, Street address: Haartmaninkatu 8, 00014, Helsinki, Finland. Juha.Klefstrom@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Eucaryotes › Animaux › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques, cycle ponté › Composés hétérocycliques bicycliques › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées en tandem › Clustered regularly interspaced short palindromic repeats › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes tumoraux › Oncogènes › Proto-oncogènes › Gènes myc › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Régions du corps › Transplants › Hétérogreffes › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Composés chimiques organiques › Amidines › Guanidines › Biguanides › Metformine › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Pharmacological reactivation of MYC-dependent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines régulatrices de l'apoptose › Protéine bcl-X › Pharmacological reactivation of MYC-dependent...